BZL101 Clinical Trial

BionovoBezielle (BZL101) Clinical Trial
Trial Status: Active, Not Recruiting

Background

  • Over 200,000 women in the US are diagnosed with breast cancer every year.
  • Breast cancer is the 2nd leading cause of cancer deaths for women.
  • Current treatments lead to intolerable side effects and ineffective control of advanced breast cancer symptoms.
  • Therapies with minimal side effects are urgently needed.

BezielleAbout Bezielle
  • Bezielle is an oral botanical drug designed for the treatment of breast cancer that targets only cancer cells but leaves normal cells intact and functioning.
  • Bionovo, Inc completed a preliminary trial to determine the side effects from Bezielle treatment and to determine if Bezielle is effective in the treatment of metastatic breast cancer .

Results of the preliminary trial:

    • 21 women with metastatic breast cancer enrolled.
    • On average, the group of women enrolled to the trial had been on 4 prior treatments for metastatic disease prior to starting Bezielle therapy.
    • 16 women on the trial were evaluable for response: 
      • 4 women had stable disease >90 days
      • 3 women had stable disease for >180 days
      • 1 woman was 1 mm short of a partial remission

Results published in: Breast Cancer Research and Treatment and tagged as a “Critical Trial” 
Read the article
[Adobe Acrobat PDF [232 KB]

Back to Top

Purpose of the study:
The purpose of the study is to determine the highest dose of Bezielle that women with metastatic breast cancer can tolerate and to determine if Bezielle is effective for the treatment of metastatic breast cancer as a sole treatment.

Back to Top


Who is eligible to participate?

  • Phase I:
    • Up to 20 women with histological stage IV metastatic breast cancer
  • Phase II, 80 women total with histological stage IV metastatic breast cancer
    • 40 women with hormone receptor positive disease
    • 40 women with hormone receptor negative disease


Key Inclusion Criteria:

  • Women 18 years or older
  • Histologically confirmed breast cancer
  • Clinical evidence of metastatic (stage IV) metastasis (other than bone metastasis)
  • Availability of estrogen receptor and HER2 over-amplification status
  • At least one measurable disease site defined by RECIST criteria, 30 days prior to study therapy
  • For the phase 2 only, no more than 2 prior cytotoxic treatments for breast cancer 
  • Life expectancy ≥ 12 weeks
  • Women of child bearing potential must agree to 2 forms of contraception during the course of the trial.

Key Exclusion Criteria:
  • Inability to understand/unwillingness to sign a written informed consent
  • Treatment within 6 weeks of study entry with antibodies/immunotherapy
  • Treatment within 2 weeks of study entry with chemotherapy, radiotherapy or any investigational agents
  • Currently using an investigational agent
  • Bisphosphonate therapy started within 4 weeks of study treatment
  • Women who report pregnancy, are breast-feeding or have a positive pregnancy test

Back to Top

Study Centers:

Bionovo, Inc has selected trial sites throughout the continental United States. For participation in the Bezielle trial please contact the Principal Investigator listed at the site nearest to you. 

Study Centers currently include locations in:Florida, Illinois, New York, North Carolina, Ohio and Texas

If you cannot find a site near you please complete the following form and a Bionovo, Inc representative will contact you as soon as possible. (Click here for contact form)

Florida Lynn Cancer Institute
21020 State Road 7
Boca Raton, FL 33486
Contact: Jacqueline Perez
Tel: 561-883-7554
JPerez@lrccw.com
Memorial Cancer Institute
Breast Cancer Center East
3700 Johnson Street
Hollywood, FL 33021
Contact: Cynthia Frankel
Tel: 954-985-6990
cfrankel@mhs.net
Memorial Cancer Institute
Breast Cancer Center West
603 N. Flamingo Road,
Suite 157
Pembroke Pines, FL 33028
Contact: Cynthia Frankel
Tel: 954-430-6868
cfrankel@mhs.net
Illinois University of Chicago Medical Center
Section of Oncology/Hematology
5841 S Maryland, MC 2115
Chicago, IL 60637
Contact: Bernie Libaie
Tel: 773-834-1758
blibao@medicine.bsd.uchicago.edu
 
New York Albert Einstein Cancer Center
1695 Eastchester Rd.
Bronx, NY 10461
Contact: Una Hopkins
Tel: 718-405-8543
uhopkins@montefiore.org
Herbert Irving Cancer Center
161 Ft. Washington Ave, A-P 1068
New York, NY 10032
Contact: Ramona Jayasena
Tel: 212-305-2705
rj2002@columbia.edu
North Carolina Duke University Medical Center
Morris Building
15118 Trent Dr
Durham, NC 27710
Contact: Viayka Kiotcheva
Tel: 919-684-5720
vlayka.liotcheva@duke.edu
 
Ohio Ohio State University
Jamescare Dublin
4019 Dublin-Granville Rd.
Dublin, OH 43019
Contact: Donna Shiels
Tel: 614-293-0065
donna.shiels@osumc.edu
 
Texas MD Anderson Cancer Center
1515 Holcombe Blvd, Box 243
Houston, TX 77030
Contact: Banu Arun
Tel: 713-792-8217
barun@mdanderson.org
 

Back to Top

Additional resources on Clinical Trials and Breast Cancer:

Breast Cancer Resource Sites

  • Breast Cancer Site: Provides breast cancer survivors with accurate information about everything from post-surgery options and products to information about insurance and intimacy issues.
  • Living Beyond Breast Cancer: A non-profit educational organization committed to empowering all women affected by breast cancer to live as long as possible with the best quality of life.
  • Susan Love website: Information on risk, prevention, and treatment for primary and metastatic breast cancer, as well as issues and information relevant to menopause, hormone replacement therapy, and other mid-life health issues.

Find out more about Clinical Trials

About the Trial Sponsor, Bionovo:
Bionovo is a publicly traded pharmaceutical company focused on discovering and developing drugs for women's health and cancer.  The company is working simultaneously on two distinct discovery approaches, one focusing on pro-apoptotic agents for cancer and a second, in the area of selective estrogen receptor modulators (SERMS) to treat severe menopausal symptoms. Both approaches are highly selective to yield products that will effectively and safely address these areas of high unmet need.  The company's clinical development strategy leverages relationships with key faculty at leading research institutions to conduct trials with recognized opinion leaders. 

To obtain more information on Bionovo, Inc., please visit our website: www.bionovo.com

Back to Top

Contact Us

Please fill out and submit the form below to find out about additional study centers for this trial near you.

* indicates a required field.

* Full Name:

* E-mail address: * Telephone Number:

Preferred contact method: E-mail Telephone

Address:
Street/PO Box:

City: State: Zip:

Distance I am willing to travel to participate in this study:

Gender
Female Male

Are you pregnant or nursing?
Yes No

Are you currently participating in a clinical trial?
Yes No

What stage of breast cancer do you have?
I II III IV Not Sure/Don't Know

Have you had a lumpectomy (surgical removal of the tumor and small amount of surrounding tissue) or a mastectomy (surgical removal of the entire breast) to treat your breast cancer?
Yes No

Has the cancer spread to other areas in your body?
Yes No

If you are someone other than the participant, and would prefer for us to communicate with you regarding this study, please submit your name and contact information below:

Full Name: Relationship to Patient:

E-mail address: Telephone Number:

Contact Preference:
Contact participant directly
Contact the person other than patient listed above
Contact both participant and other person

Additional Comments and Questions:

Type "1234" in this box to prove you're a human being:

 

Back to Top

Overview | Trial Summary | Who is Eligible | Study Centers | Additional Resources | Request Information BZL101 Overview BZL101 Trial Summary BZL101 Clinical Trial Eligibility BZL101 Study Centers Additional Resources about Breast Cancer and Clinical Trials Request Information about BZL101 Clinical Trial